Shukra Pharmaceuticals Ltd vs Wockhardt Ltd Stock Comparison
Shukra Pharmaceuticals Ltd vs Wockhardt Ltd Stock Comparison
Last Updated on: May 05, 2026
Key Highlights
The Latest Trading Price of Shukra Pharmaceuticals Ltd is ₹ 32.02 as of 05 May 15:30
. The P/E Ratio of Shukra Pharmaceuticals Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Wockhardt Ltd changed from 6.7 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 years The Market Cap of Shukra Pharmaceuticals Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Wockhardt Ltd changed from ₹ 4590 crore on March 2021 to ₹ 23133 crore on March 2025 . This represents a CAGR of 38.19% over 5 years The revenue of Shukra Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 39.95 crore. This represent the decline of -100% The revenue of Wockhardt Ltd for the Mar '26 is ₹ 1032 crore as compare to the Dec '25 revenue of ₹ 913 crore. This represent the growth of 13.03% The ebitda of Shukra Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 27.95 crore. This represent the decline of -100% The ebitda of Wockhardt Ltd for the Mar '26 is ₹ 292 crore as compare to the Dec '25 ebitda of ₹ 192 crore. This represent the growth of 52.08% The net profit of Shukra Pharmaceuticals Ltd changed from ₹ 3.16 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00%
The net profit of Wockhardt Ltd changed from ₹ 20 crore to ₹ 164 crore over 8 quarters. This represents a CAGR of 186.36%
The Dividend Payout of Shukra Pharmaceuticals Ltd changed from 10.47 % on March 2022 to 4.57 % on March 2025 . This represents a CAGR of -18.72% over 4 yearsThe Dividend Payout of Wockhardt Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .
About Shukra Pharmaceuticals Ltd
Shukra Pharmaceuticals Limited, formerly known Relish Pharmaceuticals Limited was established in March, 1993 and later on the Company name was changed from Relish Pharmaceuticals Limited to Shukra Pharmaceuticals Limited effective on September 22, 2016.
The Company is presently engaged in the business of manufacturing and trading of pharmaceuticals formulations and laboratory testing.
The company provides varieties of products to the clientele.
Their product portfolio includes Antibiotics (Penicillin), Anti Biotics (Cephalosporin), Anti Biotics, Macrolides, Quinolones, Anti Bacterial, Anti Fungal, Anti Malarial, Anti Viral, Anti Protozoal, Anti Anthelmintic, Sedative and Tranquilliser, Anti Depressant, Anti Manic, Anti Emetic, Anti Ulcer, Beta Blockers, Diuretics, Analgesic, Analgesic (NASID), Muscle Relaxants, Anti Tuberculosis, Vitamin Products, Anti Allergics, Corticosteroids, Hyper and Hypoglycemic, Others.
About Wockhardt Ltd
Wockhardt Limited, incorporated in July, 1999 is a global pharmaceutical and biotechnology organization, providing affordable, high-quality medicines for a healthier world.
The Company is India's leading research-based global healthcare enterprise in fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Speciality Hospitals.
It has 12 manufacturing locations and there are 3 locations where research and development activities are carried out.
The Company has manufacturing and research facilities in India, USA & UK and a manufacturing facility in Ireland.
It has a significant presence in USA, Europe and India, with 83% of its global revenues coming from international businesses.
Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified lnfectious Diseases Programme) for 5 of Anti-bacterial discovery programmes - 2 of them are Gram Negative and 3 Gram Positive effective against untreatable 'Superbugs'.
FAQs for the comparison of Shukra Pharmaceuticals Ltd and Wockhardt Ltd
Which company has a larger market capitalization, Shukra Pharmaceuticals Ltd or Wockhardt Ltd?
Market cap of Shukra Pharmaceuticals Ltd is 1,335 Cr while Market cap of Wockhardt Ltd is 23,163 Cr
What are the key factors driving the stock performance of Shukra Pharmaceuticals Ltd and Wockhardt Ltd?
The stock performance of Shukra Pharmaceuticals Ltd and Wockhardt Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Shukra Pharmaceuticals Ltd and Wockhardt Ltd?
As of May 5, 2026, the Shukra Pharmaceuticals Ltd stock price is INR ₹30.5. On the other hand, Wockhardt Ltd stock price is INR ₹1425.5.
How do dividend payouts of Shukra Pharmaceuticals Ltd and Wockhardt Ltd compare?
To compare the dividend payouts of Shukra Pharmaceuticals Ltd and Wockhardt Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.